ENDPOINTS

Supernus to acquire Sage Therapeutics for about $561M

Sage Therapeutics has finally found a buyer. Sage will be acquired by Supernus Pharmaceuticals for approximately $561 million, the companies announced Monday morning. Supernus is paying $8.50 per share, representing a roughly 27% premium over ...

Jun 16, 2025 - 12:40
 0
Supernus to acquire Sage Therapeutics for about $561M
Sage Therapeutics has finally found a buyer. Sage will be acquired by Supernus Pharmaceuticals for approximately $561 million, the companies announced Monday morning. Supernus is paying $8.50 per share, representing a roughly 27% premium over ...
Read More

Tags:

Previous Article

Daily briefing: Breathing patterns might be as unique as a fingerprint

Next Article

Mathematicians Hunting Prime Numbers Discover Infinite New Pattern for Finding Them

Related Posts

#ASGCT25: In three patients, Rocket’s second heart gene therapy shows promise

#ASGCT25: In three patients, Rocket’s second heart gene...

May 16, 2025  0

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

Merck, Daiichi Sankyo scrap FDA application for HER3 AD...

May 29, 2025  0

Regenxbio reports Duchenne gene therapy data from five patients

Regenxbio reports Duchenne gene therapy data from five ...

Jun 5, 2025  0